Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (Helsinki University Central Hospital) (Helsinki University Hospital)
- Development stage
- Preclinical
- Lead developer
- Helsinki University Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal microbiota transplantation (Helsinki University Central Hospital) is a biologic, live microbial therapy being developed by Helsinki University Central Hospital for the treatment of irritable bowel syndrome (IBS) associated with food intolerance. The therapy involves transplanting fecal microbiota from healthy donors into patients to modulate and restore a healthy gut microbiome. It is being investigated in the FinFMT-IBS (NCT05361785) placebo-controlled clinical trial, which specifically aims to determine if the treatment can help IBS patients on a restricted low-FODMAP diet to reintroduce these foods without worsening their intestinal symptoms. The intervention is administered via an initial colonoscopy followed by subsequent enemas.
- Other names
- fecal microbiota transplantfecal microbiota transplantation-Helsinki University Central Hospital-irritable bowel syndrome
Beyond the preview
Go deeper on fecal microbiota transplantation (Helsinki University Central Hospital) (Helsinki University Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (Helsinki University Central Hospital) (Helsinki University Hospital).